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Respiratory syncytial virus (RSV) is one of the most important causes for viral lower respiratory tract disease
in humans. There is no licensed RSV vaccine. Here, we generated recombinant inﬂuenza viruses (PR8/RSV.
HA-G) carrying the chimeric constructs of hemagglutinin (HA) and central conserved-domains of the RSV G
protein. PR8/RSV.HA-G virus showed lower pathogenicity without compromising immunogenicity in mice.
Single intranasal inoculation of mice with PR8/RSV.HA-G induced IgG2a isotype dominant antibodies and
RSV neutralizing activity. Mice with single intranasal inoculation of PR8/RSV.HA-G were protected against
RSV infection as evidenced by signiﬁcant reduction of lung viral loads to a detection limit upon RSV
challenge. PR8/RSV.HA-G inoculation of mice did not induce pulmonary eosinophilia and inﬂammation
upon RSV infection. These ﬁndings support a concept that recombinant inﬂuenza viruses carrying the RSV G
conserved-domain can be developed as a promising RSV vaccine candidate without pulmonary disease.
& 2014 Elsevier Inc. All rights reserved.
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Introduction
Respiratory syncytial virus (RSV) is the most important cause of
viral respiratory tract infections in children, and the second leading
cause of death from respiratory viral infections in the elderly (Falsey
et al., 2005; Nair et al., 2010). The ﬁrst RSV vaccine, formalininactivated RSV (FI-RSV) formulated with alum, was not protective,
associated with enhanced respiratory disease, and raised concerns
that non-live vaccines including FI-RSV and subunit protein vaccines
might also predispose to vaccine enhanced respiratory disease (ERD)
(Kapikian et al., 1969). Replicating vaccinia virus-vectored vaccines
expressing full-length RSV G or F proteins, and puriﬁed subunit
vaccines with adjuvants have been tested with little success due to
potential safety concerns (Castilow et al., 2008a, 2008b; Chang,
2011; Hancock et al., 2001; Murphy et al., 1990). Previous studies
suggest that puriﬁed RSV F or G protein vaccination also may prime
for ERD upon subsequent RSV challenge, albeit less severe than that
observed with FI-RSV (Hancock et al., 1996; Johnson et al., 1998;
Murphy et al., 1990). Live attenuated RSV vaccine candidates also
suffer from genetic instability, protective immunogenicity, residual
virulence, safety concerns in young infants, and lack of long-term
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immunity (Graham, 2011). Despite extensive efforts to develop RSV
vaccines, there is no licensed RSV vaccine to date (Graham, 2011).
RSV F and G glycoproteins are the protective antigens inducing
neutralizing antibodies against RSV infection. The central region of
RSV G (aa130–230) is relatively well conserved and contains 5 human
B cell epitopes called protectopes (Plotnicky-Gilquin et al., 1999),
including a highly immunogenic peptide (aa174–187) (Trudel et al.,
1991), and a T helper epitope (aa184–198) (Tebbey et al., 1998).
Antibodies to the central RSV G epitopes were shown to be protective
without ERD (Haynes et al., 2009; Plotnicky-Gilquin et al., 1999; Radu
et al., 2010). Importantly, monoclonal antibody 131-2G that recognizes a G peptide with 13 amino acids (aa164–176) was shown to
neutralize RSV in vivo, to block RSV G binding to CX3CR1, and to
prevent ERD (Boyoglu-Barnum et al., 2013; Haynes et al., 2009; Radu
et al., 2010). Mice that were immunized with G-deleted FI-RSV
showed similar levels of ERD but higher RSV lung viral titers
(Johnson et al., 2004). These results suggest that G-speciﬁc immune
responses are important for protection and that other RSV components have similar potential to induce ERD.
Inﬂuenza vaccines either in the form of inactivated viral split or as a
live attenuated viral platform, have been safely used in humans for
many years. Beyond protection against inﬂuenza, inﬂuenza virus
emerges as a promising vaccine vector candidate due to its protective
immune responses (Kreijtz et al., 2011) and the availability of a reverse
genetics system that allows the expression of foreign genes (Hoffmann
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et al., 2000). Li et al. (1992) generated recombinant inﬂuenza A virus
containing chimeric hemagglutinins (HAs) in which the six-aminoacid loop of antigenic site B was replaced by the corresponding
structures of the HA of H2 or H3 subtypes. Moreover, it was also
reported that the insertion of foreign epitopes from human immunodeﬁciency virus-1 (Li et al., 1993) into an antigenic site B of the HA.
Furthermore, there is no risk that the viral genome would integrate
into the host genome when inﬂuenza virus is used as a vaccine vector
because there is no DNA phase during the life-cycle of negative-sense
RNA viruses (Kittel et al., 2005). Compared to other DNA-based viral
vectors with the potential to integrate their viral DNA into the host
genome, inﬂuenza virus-based vaccine vectors therefore promise high
safety for human use. Here, as a proof-of-concept, we explored a
recombinant inﬂuenza virus as a live viral vector for mucosal delivery
of the RSV G protein conserved domain (aa131–230). We produced
recombinant inﬂuenza viruses carrying a conserved-domain of the
RSV G protein in the HA, and tested their protective efﬁcacy against
RSV and safety in comparison with FI-RSV and live RSV.

Materials and methods
Cells and viruses
293T cells (DuBridge et al., 1987) and HEp2 cells (Quan et al.,
2011) were obtained from ATCC and maintained in DMEM media.
The RSV strain A2 was originally gifted from Dr. Barney Graham.
Inﬂuenza virus A/PR/8/1934 (H1N1, abbreviated as PR8) was
grown in 10-day-old embryonated hen’s eggs at 37 1C for 2 days.
The allantoic ﬂuid was harvested and stored at  70 1C until used.
The viruses were inactivated by mixing the virus with formalin at
a ﬁnal concentration of 1:4000 (v/v) as described previously (Quan
et al., 2008). The viruses were puriﬁed by using discontinuous
sucrose gradient ultracentrifugation with layers of 20 and 60%
(wt/vol) as previously described (Song et al., 2011).
Construction of PR8/RSV.HA-G1 and PR8/RSV.HA-G2
Recombinant viruses were rescued using the pHW2000-based
eight-plasmid system that was kindly provided by Dr. Webster as
described by Hoffmann et al. (2000). The sequence encoding RSV G
protein aa131–230 was inserted between the 30 end of the HA signal
peptide sequence and the nucleotide sequences encoding the
N-terminal domain of the HA1 ectodomain of pHW2000-HA plasmid
as described (Li et al., 2005). The inserted sequence was followed by a
GGGGS or AAAPGAA peptide linker to facilitate the proper folding of the
inserted polypeptides as independent domains, respectively (Fig. 1A).
To generate recombinant viruses PR8/RSV.HA-G1 and PR8/RSV.
HA-G2, 293T cells were cotransfected with eight pHW2000 plasmids of inﬂuenza virus gene segments including the chimeric HA-G
constructs (Fig. 1A). After 48 h, the medium was collected and
inoculated to embryonated chicken eggs. After 72 h, the presence
of the rescued recombinant viruses in the allantoic ﬂuids was
conﬁrmed by hemagglutination of chicken red blood cells. Puriﬁed
viruses (2  108 PFU/ml) were prepared by discontinuous sucrose
gradient ultracentrifugation of each RSV stock (2  106 PFU/ml) and
then by resuspending in PBS to have the same PFU amount of virus.
To determine the incorporation of recombinant HA-G chimeric
proteins, the reactivity to RSV G protein monoclonal antibody (Clone
131-2G, Millipore) was analyzed using equal amounts of virus.
Immunizations and RSV challenge of mice
For animal experiments, 6- to 8-week-old female BALB/c mice
(n¼5; Harlan Laboratories) were intranasally inoculated with phosphate-buffered saline (PBS) or 500 EID50 dose (50% egg infective dose,

EID50) of PR8/RSV.HA-G1, PR8/RSV.HA-G2, or PR8 wild-type (PR8 WT)
or 2  105 PFU of RSV A2 strain under isoﬂurane anesthesia. The FIRSV control group (n¼5) was intramuscularly immunized with 50 ml
of FI-RSV (2 mg) adsorbed to aluminium hydroxide adjuvant (2 mg/
ml) (Prince et al., 2001). Blood samples were collected at 7 weeks
after immunization. All immunized mice were challenged with RSV
A2 strain (2  105 PFU) at 8 weeks after immunization. The individual
lungs, spleens, and bronchoalveolar lavage ﬂuid (BALF) samples were
removed aseptically at day 5 post-challenge (p.c.), and lung homogenates were prepared as described (Kwon et al., 2014). All animal
experiments presented in this study were approved by the Georgia
State University IACUC review boards (IACUC A11026).
Assays for antibody responses and virus titration
RSV G protein-speciﬁc antibodies (IgG, IgG1, and IgG2a) were
determined in samples by enzyme-linked immunosorbent assay
(ELISA) as previously described (Kim et al., 2012). Brieﬂy, the extracellular domain of RSV G protein with over 95% purity (200 ng/ml,
Sino biological, Beijing, China) or inactivated inﬂuenza virus (4 mg/ml)
was used as a coating antigen. The wells were washed with PBS
containing 0.05% Tween 20 (PBST) and blocked with PBST containing
3% BSA for 2 h at 37 1C. Serially diluted serum samples were added
and incubated for 1.5 h at 37 1C then horseradish peroxidase (HRP)conjugated goat anti-mouse IgG, IgG1, and IgG2a (Southern Biotechnology) were used as secondary antibodies. The tetramethybenzidine
(TMB) peroxidase substrate (Sigma-Aldrich, St. Louis, MO) was used to
develop color and optical density was read at 450 nm. RSV-speciﬁc
neutralizing antibody titers in mouse sera were measured by a
slightly modiﬁed version of a standard method as described previously (Anderson et al., 1988). Brieﬂy, mouse sera were heatinactivated at 56 1C for 45 min and serially diluted two-fold in growth
medium. Equal volumes of diluted sera were mixed with RSV A2 to
yield 300 PFU/well. RSV with or without immune serum mixture was
incubated at 33 1C, 5% CO2 for 1 h before incubation in the HEp2
monolayers. The next steps were followed by an immunoplaque assay
procedure as described (Quan et al., 2011). After ﬁxing with ice-cold
acetone–methanol and air drying, individual plaques were visualized
using anti-RSV F monoclonal antibody (131-2A, Millipore), HRP
conjugated anti-mouse IgG antibody, and 3,30 -diaminobenzidine tetrahydrochloride substrate (Invitrogen).
Analysis of cytokines
Cytokine levels in BALF were determined using ELISA kits for
IL-5 (eBioscience) and eotaxin (R&D Systems, Minneapolis, MN)
according to the manufacturers’ instructions in duplicate against a
standard curve.
Flow cytometric analysis
For analyzing phenotypes of cell population, BAL cells were
collected and then stained with ﬂuorochrome-conjugated antibodies
(anti-CD3, CD45, CD11b, CD11c, and SiglecF antibodies) as described
in previous studies (Lee et al., 2014). The lung tissues were homogenized and cells were then passed through strainer and spun on 44
and 67% Percoll gradients at 2800 rpm for 20 min. A band of cells
was harvested and washed with PBS. To determine intracellular
cytokine production, lung cells were stimulated with 5 mg/ml of
peptides corresponding to the CD4 T cell epitope G183–195 peptide
(WAICKRIPNKKPG) in the presence of Brefeldin A (BFA) (20 μg/ml) at
37 1C for 5 h. Then stimulated lung cells were surface stained using
anti-CD45-peridinin chlorophyll protein complex, anti-CD4-allophycocyanin (APC) and anti-CD8α-r-phycoerythrin (PE) antibodies and
then were permeable by using the Cytoﬁx/Cytoperm kit (BD Biosciences). Intracellular cytokines were revealed by staining the cells
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with or anti-IL-4-ﬂuorescein isothiocyanate or anti-IFN-γ-APC-Cy7
antibodies. All antibodies were purchased from eBiosciences or BD
Bioscience. Stained BAL and lung cells were analyzed using LSRFortessa (BD Biosciences) and FlowJo software (Tree Star Inc.).

Results

Lung histology of RSV-infected mice

As a proof-of-concept study to explore whether a recombinant
inﬂuenza virus carrying an RSV G conserved-central domain could
provide protection against RSV, we used the PR8 inﬂuenza virus
reverse genetics system. Two chimeric recombinant PR8/RSV
viruses were generated, each containing the RSV G conserveddomain (aa131–230) but with different linkers (PR8/RSV.HA-G1
with a GGGGS linker, PR8/RSV.HA-G2 with AAAPGAA linkers at
both conjugate sites, Fig. 1). For quantitative determination
of G domain expression on recombinant inﬂuenza/RSV viruses,
we compared PR8/RSV.HA-G1, -G2, parental PR8 WT, and
RSV for its reactivity to G protein-speciﬁc monoclonal antibody
131-2G by ELISA (Fig. 1B and C). PR8/RSV.HA-G1 with a shorter
linker was found to have 4-fold higher reactivity to
131-2G antibody than RSV. The reactivity of 131-2G antibody to
PR8/RSV.HA-G2 was similar to that of RSV. These results suggest
that recombinant inﬂuenza/RSV viruses contain RSV G domains at

For histological analysis, lung samples were ﬁxed in 10% neutral
buffered formalin for 48 h, transferred to 70% ethanol, embedded
parafﬁn blocks, sectioned into a thickness of 5 μm and stained
with hematoxylin and eosin (H&E), periodic acid-Schiff stain (PAS)
or hematoxylin and congo red (H&CR) as described (Meyerholz
et al., 2009). At least eight sections per mouse were obtained for
histopathologic analysis.
Statistical analysis
All results are expressed as the mean7standard error of the mean
(SEM). Signiﬁcant differences among treatments were evaluated by
1-way or 2-way ANOVA where appropriate. p-Values of less than or
equal to 0.05 were considered statistically signiﬁcant.

Generation of recombinant inﬂuenza virus containing an RSV G
protein conserved-domain

Fig. 1. Characterization of recombinant PR8/RSV.HA-G1 and PR8/RSV.HA-G2 viruses. (A) Schematic representation of WT and mutant HA-G constructs. (B) G protein
reactivity to PR8 WT, PR8/RSV.HA-G1, and RSV by ELISA using G protein monoclonal antibody (131-2G) after serial passages. (C) G protein reactivity to PR8 WT, PR8/RSV.HAG2, and RSV by ELISA using G protein monoclonal antibody (131-2G) after serial passages. The viruses were inactivated and then puriﬁed by using discontinuous sucrose
gradient ultracentrifugation. CT, cytoplasmic tail; TM, transmembrane domain. WT; wild-type; p2, passage 2; p10, passage 10.

Fig. 2. Growth kinetics and pathogenicity of recombinant PR8/RSV.HA-G viruses. (A) In vitro growth kinetics. Eggs were infected at 15 EID50 (50% egg infective dose) of PR8
WT, PR8/RSV.HA-G1 and PR8/RSV.HA-G2 virus. Samples were taken at 0, 12, 24, 36, and 48 h postinfection. The viral titer in the samples was determined by EID50 assay. (B
and C) Mice were inoculated intranasally with 1000 EID50 of the PR8 WT and PR8/RSV.HA-G viruses. (B) Body weight changes were monitored daily for 7 days after
inoculation. (C) Lung viral titers were determined by EID50 assay at 7 days after inoculation. Statistically signiﬁcance was determined by 1-way or 2-way ANOVA where
appropriate. Asterisks indicate signiﬁcant differences (*p o0.05 and ***p o 0.001) compared with the results in the PR8 WT group.

220

Y.-N. Lee et al. / Virology 476 (2015) 217–225

higher or similar levels compared to those in WT RSV, which is
important. In addition, the stability of the G domain expression in
the PR8/RSV.HA-G viruses was ascertained by serially passaging
the virus in eggs (Fig. 1B and C). The reactivity of 131-2G antibody
to PR8/RSV.HA-G viruses slightly decreased after 10 serial passages
probably due to a fraction of virus that might not express a
conjugate HA-G but the reactivity for RSV G domain contents
was still higher than that of RSV.
Recombinant PR8/RSV.HA-G viruses show attenuated phenotypes
To determine in vitro viral growth kinetics, eggs were infected at
a 15 EID50 of PR8 WT, PR8/RSV.HA-G1 or PR8/RSV.HA-G2. At various
times after infection, viral titers in allantoic ﬂuids were quantiﬁed by
EID50 assay (Fig. 2A). The growth kinetics of PR8/RSV.HA-G1 or PR8/
RSV.HA-G2 in eggs was found to be comparable to that of PR8 WT.
To compare replication and pathogenicity of PR8/RSV.HA-G and
PR8 WT viruses, we infected BALB/c mice with 1000 EID50 of each
virus. Mice infected with PR8 WT virus showed a progressive weight
loss over 12% from day 4 to day 7 post-infection. In contrast, mice
inoculated with PR8/RSV.HA-G viruses did not display weight losses
(Fig. 2B). The recombinant viral vaccine-inoculated mice showed
signiﬁcantly lower lung viral titers compared with those in PR8
WT-inoculated mice (po0.001, Fig. 2C). Despite similar growth
kinetics in eggs, the recombinant PR8/RSV.HA-G viruses were attenuated in terms of viral replication and did not cause weight losses in
mice compared to PR8 WT.

Inoculation with PR8/RSV.HA-G viruses induces RSV G speciﬁc
antibody
BALB/c mice received a single intranasal administration with
PR8/RSV.HA-G1, PR8/RSV.HA-G2, or PR8 WT at 500 EID50 dose.
Seven weeks after immunization, we measured serum antibody
titers (Fig. 3). RSV G-speciﬁc IgG antibodies were detected at high
levels in the live RSV group (331.37158.5 ng/ml). RSV G-speciﬁc
IgG antibody concentrations in the PR8/RSV.HA-G1 (155.6 7
95.4 ng/ml) and the PR8/RSV.HA-G2 group (90.4 748.9 ng/ml)
were approximately 4.6- and 2.5-fold higher than those in the
FI-RSV group (33.8 711.6 ng/ml) (Fig. 3A). Moreover, the PR8/RSV.
HA-G1 and PR8/RSV.HA-G2 groups showed higher ratios of IgG2a/
IgG1 isotype antibodies than the FI-RSV and live RSV group
(Fig. 3B). The PR8/RSV.HA-G1 and PR8/RSV.HA-G2 groups showed
RSV neutralizing antibody titers of 5.2 7 0.73 log2 and 5.8 71.11
log2, respectively. The FI-RSV and live RSV group showed lower
RSV neutralizing titers of 4.3 70.3 and 4.4 7 0.2 log2, respectively
(Fig. 3C), but there were no signiﬁcant differences among the
groups. A partial domain (aa131–230) of RSV G protein in
recombinant viruses might limit the levels of RSV G-speciﬁc IgG
antibody responses in the PR8/RSV.HA-G groups compared to
those in the live RSV group despite comparable RSV neutralizing
activity. All mice immunized with recombinant or PR8 WT virus
showed similar levels of PR8 virus speciﬁc-IgG antibodies (Fig. 3D).
These results provide evidence that recombinant inﬂuenza/RSV
viruses are able to raise RSV neutralizing antibody responses.

Fig. 3. Immunogenicity of recombinant PR8/RSV.HA-G1 and PR8/RSV.HA-G2 viruses. Mice were inoculated intranasally with PR8 WT, PR8/RSV.HA-G1 and PR8/RSV.HA-G2
virus (500 EID50, n¼ 5). Serum samples were collected at 7 weeks after immunization. (A) IgG antibodies speciﬁc to G protein in serum. ELISA was performed for serum
antibodies speciﬁc for G protein using serially diluted samples. (B) Ratios of IgG2a/IgG1 isotype antibodies speciﬁc for the G protein. (C) RSV neutralization titers. (D) IgG
antibodies speciﬁc for inactivate PR8 virus. ELISA was performed for serum antibodies speciﬁc for PR8 virus. Error bars indicates mean 7 SEM. N.d., not determined.
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Recombinant PR8/RSV.HA-G virus confers protection against RSV
infection
To assess the protective efﬁcacy of recombinant inﬂuenza/RSV
vaccines, groups of mice were challenged with RSV A2 (2  105 PFU/
mouse) at 8 weeks after immunization. PBS-immunized mice
showed moderate weight loss ( 4%) after RSV challenge. By contrast,
weight loss was not observed with PR8/RSV.HA-G1, PR8/RSV.HA-G2,
FI-RSV, or live RSV-immunized mice, improving clinical outcomes
after RSV challenge (Data not shown). Clearance of lung viral loads is
an important parameter in assessing the efﬁcacy of protection
against RSV infection. Lung tissues were collected from individual
mice at day 5 p.c. and viral titers in lung samples were determined
using an immunoplaque assay. The highest RSV titer was detected in
PBS-immunized mice. FI-RSV, live RSV and recombinant PR8/RSV.
HA-G-inoculated mice showed signiﬁcantly lower lung RSV titers
compared with those in PBS-immunized mice (po0.001, Fig. 4A).
To better understand mechanism of protection by recombinant
viral RSV vaccines, RSV G-speciﬁc antibody and immune responses
in BALF were determined at an early time post challenge. BALF
samples from the groups of mice that were immunized with PR8/
RSV.HA-G1 and PR8/RSV.HA-G2 showed higher levels of RSV Gspeciﬁc IgG concentrations than those from PBS, PR8 WT, FI-RSV,
and live RSV-immunized mice at day 5 p.c. (Fig. 4B). The levels of
IL-5 (Fig. 4C) and eotaxin (Fig. 4D) in mice immunized with FI-RSV
were signiﬁcantly higher than those in the other groups.
To determine T cell responses, we measured IFN-γ or IL-4
cytokine-producing lung cells after in vitro stimulation with
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G183–195 peptide (Fig. 5). FI-RSV immune mice showed the highest
levels of IL-4-producing G183–195-speciﬁc CD4 þ T cells whereas the
PR8/RSV.HA-G1 and PR8/RSV.HA-G2 groups did not induce RSV
speciﬁc CD4 þ T cell responses (Fig. 5A). IFN-γ-producing G183–195speciﬁc CD4 þ T cells were not signiﬁcantly induced in the recombinant PR8/RSV vaccine groups compared with the FI-RSV or PR8 WT
group (po0.001, Fig. 5B). It is speculated that no induction of RSVspeciﬁc T cells might be due to the complete control of lung viral
loads by RSV speciﬁc antibodies in this live RSV group.
PR8/RSV.HA-G virus does not cause pulmonary inﬂammation upon
RSV infection
Eosinophils with the phenotypes of CD45 þ CD11c  CD11b þ
SiglecF þ are known to be enriched in inﬂamed lung tissues
(Stevens et al., 2007). At day 5 p.c., the FI-RSV group prominently
induced a population with CD45 þ CD11c  CD11b þ SiglecF þ cells
(Fig. 6A), which was approximately 73% out of the CD45 þ CD11c 
granulocyte populations (Fig. 6B). Importantly, the group of mice
immunized with PR8/RSV.HA-G1, PR8/RSV.HA-G2, PR8 WT, and
live RSV did not show such a distinct population of
CD11b þ SiglecF þ cells (Fig. 6A and B). Moreover, there was
signiﬁcantly higher cellularity of inﬁltrating cells in BAL ﬂuids
from mice in the FI-RSV group compared to those from other
groups (Fig. 6C).
Examination of pulmonary histopathology is important in
assessing the safety of RSV vaccine candidates. Lung tissue sections
in each group of mice were examined for inﬂammation at

Fig. 4. Recombinant PR8/RSV.HA-G1 and PR8/RSV.HA-G2 confer protection against RSV. Mice that were inoculated intranasally with PR8 WT, PR8/RSV.HA-G1, or PR8/RSV.
HA-G2 were challenged with RSV A2 (n¼ 5). (A) Lung RSV titers were determined using an immunoplaque assay at day 5 p.c. (B) Levels of G-speciﬁc IgG antibodies were
determined in BALF collected from immunized mice at day 5 p.c. with RSV. Antibody levels were determined by ELISA using the G protein as a coating antigen. IL-5 (C) and
eotaxin (D) in BALF were determined from immunized mice at day 5 p.c. IL-5 and eotaxin were determined by cytokine ELISA kits. Data represent mean7 SEM. Statistically
signiﬁcance was determined by 1-way ANOVA. Asterisks indicate signiﬁcant differences (npo 0.05, nnp o 0.01, and nnnpo 0.001) compared with the results in the PBS and
PR8 WT groups (A) or FI-RSV group (C, D).
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day 5 p.c. (Fig. 7). FI-RSV-immunized mice displayed a massive
inﬂux of inﬂammatory cells around pulmonary airways and
thickened alveolar layers, presenting heavily inﬂamed lung tissues.
In contrast, lung tissues from mice immunized with PR8/RSV.HAG1, PR8/RSV.HA-G2, or live RSV did not show an obvious sign of
inﬂammation (Fig. 7A). Alveolar epithelium appeared to be normal
in lung tissue histology from recombinant inﬂuenza/RSV or live

RSV-immunized mice. PBS or PR8 WT control mice infected with
RSV showed a slight level of interstitial pneumonia as indicated by
inﬁltrates of inﬂammatory cells and thickened alveolar layers in
the H&E staining of lung tissue sections.
Lung sections were stained with PAS to visualize mucus production. Representative PAS-stained sections of lungs from the mice are
shown in the middle row of Fig. 6A. These sections were scored for

Fig. 5. Recombinant PR8/RSV.HA-G viruses do not induce RSV-speciﬁc T cell responses. Lung cells were harvested, stimulated with G183–195, and stained with CD45, CD4, and
CD8α surface marker antibodies and intracellularly stained with IL-4 (A) or IFN-γ (B) antibodies, and then analyzed by ﬂow cytometry. Data represent mean number plus SEM
of IL-4- or IFN-γ-secreting CD4 þ T cells per lung from ﬁve individual mice. Statistically signiﬁcance was determined by 1-way ANOVA. Asterisks indicate signiﬁcant
differences (*p o 0.05, **p o 0.01 and ***p o0.001) compared with the results in the FI-RSV.

Fig. 6. PR8/RSV.HA-G1 and PR8/RSV.HA-G2 viruses do not induce eosinophil inﬁltration upon RSV challenge. Cells in BALF samples collected at 5 day p.c. were stained with
anti-CD45, CD11b, CD11c, and Siglec-F antibodies. (A) Representative dot plots of CD11b þ SiglecF þ cells (eosinophils). Number in the dot plots indicates percentages among
CD45 þ CD11c  granulocytes. (B) The mean percentage data are presented as mean 7 SEM. (C) Total BAL cell counts were determined. Data represent mean 7 SEM.
Statistically signiﬁcance was determined by 1-way ANOVA. Asterisks indicate signiﬁcant differences (*p o 0.05, **p o0.01, and ***p o 0.001) compared with the results in the
FI-RSV group.
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Fig. 7. Histopathological changes in lungs from mice after RSV challenge. (A) Photomicrographs of H&E, PAS, and H&CR stained lung tissue sections from mice at day 5 p.c.
Scale bars for H&E and PAS indicate 100 mm and for H&CR indicate 20 mm. The insets in H&CR images are details of eosinophil inﬁltration in lungs. (B) Percentages of PAS
positive staining. Tissue sections stained with PAS were scored as percentages of 10 individual airways in each mouse. Each symbol represents one airway. (C) Inﬂammation
scores of H&CR staining. Pulmonary eosinophils per 40  ﬁeld counts in two different regions of each mouse. Data represent mean 7 SEM. Statistically signiﬁcance was
determined by 1-way ANOVA. Asterisks indicate signiﬁcant differences (***po 0.001) compared with the results in the FI-RSV group.

percentages of airway linings showing PAS staining (Fig. 7B). The
recombinant inﬂuenza/RSV immunized-mice showed signiﬁcantly
less PAS staining than the FI-RSV-immunized mice (po0.001). To
estimate the degree of lung eosinophilia, we examined H&CR stained
lung sections (bottom row, Fig. 7C). The accumulation of H&CR
positive eosinophils was signiﬁcantly greater in lungs of FI-RSV
immunized-mice than in those of animals that were vaccinated with
recombinant inﬂuenza/RSV.HA-G, PR8 WT or live RSV (po0.001).

Discussion
The majority of protective neutralizing antibodies generated by
inﬂuenza vaccines recognizes the HA glycoprotein on the viral
surface (Mozdzanowska et al., 2003). This study presents results
supporting inﬂuenza virus HA as a possible carrier molecule for the
delivery of protective antigens in a replicating viral vector. HA
has also been reported to have adjuvant-like effects when coadministered with virus-like particles (Cox et al., 2004; Kang et al.,
2004). Since the N-terminal regions of HA1 can differ in length,
there may be sufﬁcient structural ﬂexibility in this HA location to
accommodate extra polypeptide segments without interfering with
HA receptor binding and fusion functions (Nobusawa et al., 1991). To

test this hypothesis, we molecularly designed and constructed new
recombinant inﬂuenza viruses containing the conserved-domain of
the RSV G protein at the N-terminus of inﬂuenza virus HA. We
demonstrated that the conserved-domain of the RSV G protein can
be incorporated as an insert into the HA protein without signiﬁcant
effects on HA immunogenicity (Fig. 3D) or replication (Fig. 2A).
Despite the fact that recombinant viruses of inﬂuenza/RSV were
moderately attenuated based on their low lung viral titers and no
body weight changes in mice after inoculation, these recombinant
vaccines were found to confer protection against inﬂuenza virus
(data not shown). Our data provide proof-of-concept that these
recombinant virus vaccines can be safe, immunogenic, and confer
protection against inﬂuenza and RSV after a single mucosal delivery.
Puriﬁed full-length ectodomain G protein vaccines were demonstrated to induce Th2 type immune responses (Hancock et al., 1996;
Johnson et al., 1998). Conjugate vaccines consisting of the G protein
central domain (aa130–230) and the albumin-binding domain of
streptococcal protein G (BBG2Na) were shown to be protective without
obvious lung disease, but to induce undesirable IL-13-producing T cells
and pulmonary eosinophilia (De Waal et al., 2004; Power et al., 2003;
Siegrist et al., 1999). In contrast, our results demonstrated that
recombinant inﬂuenza/RSV viral vaccines induced favorable Th1 type
antibody responses. Therefore, a restricted domain of the RSV G
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protein in a platform that presents this G fragment in a safe live vector
may inﬂuence the pattern of host immune responses, which may
confer protection against RSV without pulmonary RSV disease. In
support of this concept, protection against RSV was provided by two
immunizations with recombinant inﬂuenza virus harboring multiple
RSV F and G-derived epitopes that were introduced into the nonstructural (NS1) protein (Bian et al., 2014). Probably due to the nature
of intracellular expression of RSV G and F epitopes together with NS1
genes, protective efﬁcacy of single G or F epitope-containing recombinant inﬂuenza virus was reported to be low (Bian et al., 2014). Results
in our study showed that G domains in recombinant PR8/RSV.HA-G
viruses were incorporated into virions at a comparable or higher level
as in RSV and a single dose may be sufﬁcient to confer protection.
Therefore, the insertion of the foreign proteins into the HA proteins is a
promising vector platform for presenting viral vaccine antigens. It
would be expected that recombinant inﬂuenza virus vaccines with
RSV fusion (F) or G plus F epitopes in a form of HA conjugates might
be even more effective in conferring protection against RSV.
Considering a previous report that immunization with recombinant vaccinia viruses expressing the full-length wild type or secreted
RSV G protein caused severe RSV lung disease (Johnson et al., 1998),
it is noticeable to underscore that PR8/RSV.HA-G conferred protection against RSV without undesirable lung disease. It was reported
that ERD was associated with eosinophils’ inﬁltration (Kim et al.,
1969), elicitation of aberrant T cell responses (Castilow and Varga,
2008), and immune complex deposition in small airways (Polack
et al., 2002). It is possible that induction of neutralizing antibodies
without signiﬁcant RSV-speciﬁc T cell responses by recombinant
PR8/RSV.HA-G might have contributed to preventing RSV lung
disease. In contrast, the FI-RSV group showed high levels of IL-5,
eotaxin, and eosinophils as well as IL-4-producing T cells. Therefore,
our strategy of developing recombinant inﬂuenza virus containing
the conserved RSV G protein domain may be a promising approach
to induce neutralizing antibodies against RSV, preventing the
induction of undesirable cellular responses to RSV. Both recombinant PR8/RSV.HA-G1 and -G2 viruses were attenuated in mice as
evidenced by low lung viral replication and no body weight loss.
Nonetheless, we would not consider using the PR8 wild-type genetic
backbone tested in this study for potential translation into humans.
Live attenuated inﬂuenza vaccine (LAIV) has been approved in the
United States, Canada, and Europe for vaccination against inﬂuenza
(Moore, 2013; Scott et al., 2012). Therefore, testing chimeric HA-G
and HA-F neutralizing epitope constructs in the backbone of LAIV
should be an important objective for future studies.
In conclusion, recombinant inﬂuenza viruses containing the
conserved domain of the RSV G protein were found to provide
protection without the risk of potentially priming for enhanced
disease in mice after RSV challenge. Recombinant PR8/RSV.HA-G
vaccines elicited Th1-biased G-speciﬁc IgG2a antibodies and signiﬁcantly reduced lung viral RSV replication. These ﬁndings in this
study not only demonstrate the efﬁcacy of recombinant inﬂuenza
vaccines expressing RSV proteins, but may also become instrumental
for improving the molecular approaches of developing bivalent or
multivalent respiratory viral vaccines. Our results provide evidence
for compelling proof-of-concept that recombinant inﬂuenza/RSV.
HA-G viruses can be developed into a promising RSV vaccine
candidate, which may combine an appropriate balance of inducing
protective neutralizing antibodies and avoiding undesirable RSV
cellular immune responses responsible for lung immunopathology.
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